0QBO N Stock Overview

Engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. More details

0QBO N fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	3/6
Past Performance	3/6
Financial Health	2/6
Dividends	3/6

Rewards

Earnings are forecast to grow 10.99% per year

Earnings grew by 1.2% over the past year

Risk Analysis

Shares are highly illiquid

Has a high level of debt

My Notes

Capture your thoughts, links and company narrative

Coloplast A/S Competitors

Cooper Companies

NasdaqGS:COO

US$18.6b

Alcon

SWX:ALC

CHF 38.2b

HOYA

TSE:7741

JP¥7.1t

Align Technology

NasdaqGS:ALGN

US$16.7b

Price History & Performance

Summary of share price highs, lows and changes for Coloplast
Historical stock prices
Current Share Price	DKK 2,082.59
52 Week High	DKK 2,427.29
52 Week Low	DKK 2,082.59
Beta	0.22
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	26.87%
Change since IPO	65.47%

Recent updates

Shareholder Returns

	0QBO N	MX Medical Equipment	MX Market
7D	0%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how 0QBO N performed against the MX Medical Equipment industry.

Return vs Market: Insufficient data to determine how 0QBO N performed against the MX Market.

Price Volatility

Is 0QBO N's price volatile compared to industry and market?
0QBO N volatility
0QBO N Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: 0QBO N has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 0QBO N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1954	14,973	Kristian Villumsen	www.coloplast.com

Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand.

Coloplast A/S Fundamentals Summary

How do Coloplast's earnings and revenue compare to its market cap?
0QBO N fundamental statistics
Market cap	Mex$499.55b
Earnings (TTM)	Mex$12.47b
Revenue (TTM)	Mex$62.55b

40.0x

P/E Ratio

8.0x

P/S Ratio

Is 0QBO N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QBO N income statement (TTM)
Revenue	DKK 24.07b
Cost of Revenue	DKK 7.68b
Gross Profit	DKK 16.39b
Other Expenses	DKK 11.59b
Earnings	DKK 4.80b

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

Aug 17, 2023

Earnings per share (EPS)	22.60
Gross Margin	68.09%
Net Profit Margin	19.94%
Debt/Equity Ratio	295.4%

How did 0QBO N perform over the long term?

See historical performance and comparison

Dividends

2.2%

Current Dividend Yield

88%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/05/23 19:57
End of Day Share Price	2023/02/23 00:00
Earnings	2023/03/31
Annual Earnings	2022/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Coloplast A/S is covered by 48 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier
Robert Bate	Barclays
Hassan Al-Wakeel	Barclays

0QBO N Stock Overview

Rewards

Risk Analysis

Coloplast A/S Competitors

NasdaqGS:COO

US$18.6b

SWX:ALC

CHF 38.2b

TSE:7741

JP¥7.1t

NasdaqGS:ALGN

US$16.7b

Price History & Performance

Recent News & Updates

An undisclosed buyer acquired Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B).

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Recent updates

An undisclosed buyer acquired Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B).

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Less than half of directors are independent

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of kr.14.00 per share

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Investor sentiment improved over the past week

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Shareholder Returns

Price Volatility

About the Company

Coloplast A/S Fundamentals Summary

40.0x

8.0x

Earnings & Revenue

Dividends

2.2%